Research & DevelopmentGermany to Provide 100,000 Mpox Vaccine Doses to Combat...

Germany to Provide 100,000 Mpox Vaccine Doses to Combat Outbreak in Africa

-

Germany has provided 100,000 doses of the Mpox vaccine from its armed forces to help combat the ongoing outbreak in Africa, a government spokesperson said.
This contribution is expected to bring swift relief to the continent and support the countries battling the virus. In addition to the vaccine donation, Germany will offer the WHO flexible human resources and financial support through various arrangements in the fight against Mpox. The German government will also assist African nations through the GAVI vaccine alliance, as part of its partnership with the continent.

Germany has approximately 117,000 doses of the Jynneos vaccine in its military supply, which were purchased in 2022. Some of these doses will be reserved for the protection of officers traveling to different stations, as confirmed by a defense ministry spokesperson on Monday.
The spokesperson also indicated that any further decisions regarding restocking vaccines would require additional discussions.
Mpox has been declared a global public health emergency by the WHO, particularly after an outbreak was reported in the Democratic Republic of Congo and subsequently spread to neighboring countries. The new variant of the virus, specifically Clade Ib, is of particular concern to experts due to its rapid propagation.
The German government is also seeking the quickest way to deliver the vaccines to the affected regions, particularly the Democratic Republic of Congo, Burundi, and other East African nations, according to a foreign ministry official.

Life Sciences Voice Logo mobile
+ posts

Latest news

Gilead Secures Arenavirus Vaccine Programs from Hookipa for $10 Million

Gilead Sciences has acquired exclusive ownership of two arenavirus-based immunotherapy programs for hepatitis B (HBV) and human immunodeficiency virus...

Sanofi Acquires Vigil Neuroscience for $470M to Boost Alzheimer’s Drug Pipeline

Sanofi is acquiring Vigil Neuroscience for $470 million to expand its Alzheimer’s drug portfolio, focusing on TREM2-targeting therapies like...

Moderna Delays Flu-COVID Combo Vaccine Filing Amid FDA Request

Moderna has announced that it is withdrawing its application for approval from the U.S. Food and Drug Administration (FDA)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you